Bioprocessing and Artificial Intelligence in Cell Therapies: China’s Model

When:  Aug 7, 2024 from 09:00 to 10:00 (SG)


Elizabeth Lam

Bioprocessing and Artificial Intelligence in Cell Therapies: China’s Model

Presented by the ISCT Asia Regional Executive Committee 
Sponsored by REGEN-αGEEK (Haining) Biotechnology Co., Ltd. 


China has developed advances in immune cell therapies, but there is relatively little information on stem cell based therapies. In this webinar, we bring together 2 researchers who have spent 10 years developing stem cell research, bioprocessing and machine learning skills in Singapore and have since started their own company and research teams in China. Prof. Zhang Zhiyong, Founder and CEO of REGEN-αGEEK (Haining) Biotechnology Co., Ltd. and Prof. Yin Lu from Nanchang University will be speakers.

Key Learning Objectives: 
  • Understand the bioprocessing challenges in cell therapy manufacturing in China and the solutions provided.
  • Understand how machine learning is helping to guide stem cell therapy for osteoarthritis.
  • Discuss collaborations and engaging Chinese researchers with ISCT.


Prof. Steve Oh, PhD
Past ISCT Asia Regional VP

Chief Scientific Advisor



Steve has 34+ years of experience in the biotechnology industry and academia. He was formerly at the Agency for Science and Technology (A*STAR) for 22 years serving as Institute Professor at the Bioprocessing Technology Institute (BTI). In total, he has managed $34M of grants including the ASTEM (Allogeneic Manufacturing Stem Cell) programme between 2019-2022 for donor to patient manufacturing and delivery of mesenchymal stromal cells (MSC). Steve attends actively as an Adviser and Reviewer on several premier Cell & Gene Therapy Societies such as the International Society of Cell & Gene Therapy (ISCT), he was Asia Pacific VP from 2015-2017.


Prof. Zhiyong Zhang


REGEN-αGEEK (Haining) Biotechnology Co., Ltd.


Professor Zhiyong Zhang is a professor at Guangzhou Medical University (GMU) and the founding director of the Translational Research Centre of Regenerative Medicine and 3D Printing Technologies at GMU, as well as the Biomedical Engineering Research Center of Guangdong Province. Additionally, he serves as the Group Leader of the State Key Lab of Respiratory Disease in China. Previously, he was a Professor/Group Leader at Shanghai Jiao Tong University and the National Tissue Engineering Centre of China. He has been granted several talent scheme program awards, including the awardee of the First Prize of National Science and Technology Progress Award of China (Top scientific awards in China) and the National Talent Program of China (China’s Recruitment Program of Global Experts), the "Eastern Scholar" Distinguished Professor, and the “Outstanding Medical Academic Leader”. He has filed more than 30 patents, published over 80 academic papers in international journals such as Advanced Science, Bioactive Materials, Small, Biomaterials, and authored five book chapters, also he has awarded more than 20 Research Grants (30M RMB) and has been invited over 40 Keynote lectures at international conferences.

With a long-standing focus on clinical translational research in stem cells and regenerative medicine, Prof. Zhang has successfully translated several technologies into clinical practice. He dedicated to create the DASEA Bio-manufacturing platform, to achieve the "5" goals for the scalable manufacturing of biological products such as cells and exosomes: Digitalized, Automated, Scalable, Enclosed, Activated. The DASEA Bio-manufacturing platform can overcome the bottleneck issues associated with traditional 2D cell culture tech, reduce production cost significantly, enhance cell quality and stability, expedite clinical translation and industrialization. The stem cells and exosomes prepared by DASEA have obtained quality inspection reports from the NIFDC and been recognized by China NMPA, as well as several large tertiary hospitals to conduct multiple clinical trials. These clinical studies have demonstrated excellent therapeutic outcomes, showcasing the safety and effectiveness of the DASEA Biomanufacturing Platform.

Prof. Lu Yin

Principal Investigator

Jiangxi Institute of Respiratory Diseases


Lu Yin is a professor at the First Affiliated Hospital of Nanchang University and a principal investigator at the Jiangxi Provincial Key Laboratory of Respiratory Disease. He also serves as a committee member of the Medical Innovation and Translation Branch of Jiangxi Integrative Medicine Society, and a member of the Youth Working Committee of Jiangxi Biochemistry and Molecular Biology Society. He was a recipient of the Research Fund for International Excellent Young Scientists awarded by the National Natural Science Foundation of China, and was selected for the “Two-Thousand” Talent Program of Jiangxi Province. Before assuming his current roles in China, Lu Yin gained valuable experiences as a research fellow at the Singapore-MIT alliance for Research and Technology, the National University of Singapore, and the Agency for Science, Technology and Research (A*STAR Singapore). His research focuses on developing effective and consistent stem cell therapy solutions through a synergistic integration of microfluidic, machine-learning, and conventional molecular biology technologies. Lu Yin has led 5 national research grants in China and Singapore. He was also a team leader representing the Bioprocessing Technology Institute of A*STAR on 4 collaborative projects with esteemed international industries. He has published over 20 research articles in reputable journals such as Biomaterials, Lab on a Chip, etc., and authored one international academic book chapter. He has been invited to present his research at international conferences hosted by the International Society for Cell & Gene Therapy, Tissue Engineering International & Regenerative Medicine Society, and Biomedical Engineering Society.